RARE - Ultragenyx Pharmaceutical Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Novato,
United States
Type: Equity
RARE price evolution
RARE
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $213.58 | $72.58 | $102.06 | $85.77 |
| Short term investments | $363.63 | $369.52 | $449.92 | $543.59 |
| Net receivables | $73.39 | $79.26 | $70.52 | $42.99 |
| Inventory | $33.97 | $31.8 | $28.26 | $26.62 |
| Total current assets | $732.18 | $599.19 | $702.14 | $766.34 |
| Long term investments | $199.9 | $86.11 | $71.83 | $90.41 |
| Property, plant & equipment | $290.57 | $323.24 | $308.21 | $300.82 |
| Goodwill & intangible assets | $210.68 | $201.71 | $202.64 | $203.58 |
| Total noncurrent assets | $758.83 | $638.95 | $609.17 | $617.07 |
| Total investments | $563.53 | $455.63 | $521.75 | $634 |
| Total assets | $1491.01 | $1238.14 | $1311.31 | $1383.4 |
| Current liabilities | ||||
| Accounts payable | $42.11 | $33.36 | $42.12 | $58.98 |
| Deferred revenue | ||||
| Short long term debt | $12.6 | $12.07 | $10.88 | $11.26 |
| Total current liabilities | $280.44 | $253.98 | $244.38 | $218.18 |
| Long term debt | $30.57 | $34.55 | $14.85 | $17.34 |
| Total noncurrent liabilities | $935.16 | $952.45 | $937.9 | $944.74 |
| Total debt | $43.17 | $46.62 | $25.73 | $28.6 |
| Total liabilities | $1215.6 | $1206.43 | $1182.28 | $1162.92 |
| Shareholders' equity | ||||
| Retained earnings | -$3387.66 | -$3264.47 | -$3104.82 | -$2944.99 |
| Other shareholder equity | $0.65 | -$2.24 | -$3.1 | -$3.97 |
| Total shareholder equity | $275.41 | $31.71 | $129.03 | $220.48 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $213.58 | $132.94 | $307.58 | $713.53 |
| Short term investments | $363.63 | $614.82 | $432.61 | $488.01 |
| Net receivables | $73.39 | $40.45 | $28.43 | $23.09 |
| Inventory | $33.97 | $26.77 | $16.23 | $13.05 |
| Total current assets | $732.18 | $883.9 | $856.6 | $1295.3 |
| Long term investments | $199.9 | $154.5 | $293.86 | $165.88 |
| Property, plant & equipment | $290.57 | $285.69 | $176.18 | $114.04 |
| Goodwill & intangible assets | $210.68 | $204.51 | $175.19 | $175.52 |
| Total noncurrent assets | $758.83 | $661.54 | $665.79 | $464.25 |
| Total investments | $563.53 | $769.32 | $726.47 | $653.89 |
| Total assets | $1491.01 | $1545.44 | $1522.4 | $1759.56 |
| Current liabilities | ||||
| Accounts payable | $42.11 | $43.27 | $17.14 | $12.92 |
| Deferred revenue | $1.48 | $9.08 | $66.57 | |
| Short long term debt | $12.6 | $11.78 | $11.07 | $8.98 |
| Total current liabilities | $280.44 | $261.21 | $181.37 | $189.61 |
| Long term debt | $30.57 | $19.81 | $30.9 | $39.25 |
| Total noncurrent liabilities | $935.16 | $931.74 | $418.47 | $415.57 |
| Total debt | $43.17 | $31.59 | $41.97 | $48.23 |
| Total liabilities | $1215.6 | $1192.95 | $599.84 | $605.18 |
| Shareholders' equity | ||||
| Retained earnings | -$3387.66 | -$2781.02 | -$2073.6 | -$1619.58 |
| Other shareholder equity | $0.65 | -$0.84 | -$1.4 | $0.69 |
| Total shareholder equity | $275.41 | $352.49 | $922.56 | $1154.38 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $127.39 | $98.05 | $108.31 | $100.5 |
| Cost of revenue | $10.99 | $9.91 | $12.26 | |
| Gross Profit | $115.34 | $87.06 | $98.39 | $88.24 |
| Operating activities | ||||
| Research & development | $157.25 | $164.95 | $165.7 | |
| Selling, general & administrative | $74.92 | $81.4 | $76.65 | |
| Total operating expenses | $237.39 | $232.86 | $248.34 | $242.34 |
| Operating income | -$145.8 | -$149.95 | -$154.1 | |
| Income from continuing operations | ||||
| EBIT | -$159 | -$159.1 | -$163.48 | |
| Income tax expense | -$3.7 | $0.65 | $0.73 | $0.49 |
| Interest expense | $1.89 | |||
| Net income | ||||
| Net income | -$123.19 | -$159.65 | -$159.83 | -$163.97 |
| Income (for common shares) | -$159.65 | -$159.83 | -$163.97 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $434.25 | $363.33 | $351.41 | $271.03 |
| Cost of revenue | $28.32 | $16.01 | $6.13 | |
| Gross Profit | $389.04 | $335.01 | $335.4 | $264.9 |
| Operating activities | ||||
| Research & development | $705.79 | $497.15 | $412.08 | |
| Selling, general & administrative | $278.14 | $219.98 | $182.93 | |
| Total operating expenses | $958.25 | $983.93 | $717.13 | $595.02 |
| Operating income | -$648.92 | -$381.74 | -$330.12 | |
| Income from continuing operations | ||||
| EBIT | -$701.73 | -$452.98 | -$185.36 | |
| Income tax expense | -$1.82 | $5.7 | $1.04 | $1.21 |
| Interest expense | $0.4 | |||
| Net income | ||||
| Net income | -$606.64 | -$707.42 | -$454.02 | -$186.57 |
| Income (for common shares) | -$707.42 | -$454.02 | -$186.57 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$123.19 | -$159.65 | -$159.83 | -$163.97 |
| Operating activities | ||||
| Depreciation | $8.22 | $7.19 | $5.36 | $5.24 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $33.74 | $34.88 | $34.65 | $31.95 |
| Total cash flows from operations | -$83.9 | -$117.87 | -$116.16 | -$156.87 |
| Investing activities | ||||
| Capital expenditures | -$1.6 | -$3.69 | -$13.94 | -$25.03 |
| Investments | -$105.15 | $68.42 | $116.25 | $140.29 |
| Total cash flows from investing | -$107.02 | $64.3 | $99.42 | $111.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $330.61 | $25.23 | $33.08 | -$0.75 |
| Net borrowings | ||||
| Total cash flows from financing | $330.61 | $25.23 | $33.02 | -$0.72 |
| Effect of exchange rate | $1.1 | -$0.72 | -$0.14 | $0.21 |
| Change in cash and equivalents | $140.79 | -$29.06 | $16.14 | -$46.07 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$606.64 | -$707.42 | -$454.02 | -$186.57 |
| Operating activities | ||||
| Depreciation | $26.01 | $18.22 | $13.24 | $12.26 |
| Business acquisitions & disposals | -$75.03 | |||
| Stock-based compensation | $135.23 | $130.38 | $104.95 | $85.73 |
| Total cash flows from operations | -$474.81 | -$380.46 | -$338.69 | -$132.22 |
| Investing activities | ||||
| Capital expenditures | -$44.27 | -$116.12 | -$73.09 | -$43.91 |
| Investments | $219.81 | -$69.66 | -$121.34 | -$129.66 |
| Total cash flows from investing | $168 | -$291.65 | -$195.37 | -$179.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $388.17 | $10.81 | $119.04 | $600.51 |
| Net borrowings | ||||
| Total cash flows from financing | $388.14 | $501.21 | $118.55 | $600.27 |
| Effect of exchange rate | $0.46 | -$1.07 | -$1.19 | $1.12 |
| Change in cash and equivalents | $81.8 | -$171.98 | -$416.71 | $290.05 |
News
Fundamentals
| Market cap | $3.57B |
|---|---|
| Enterprise value | $3.40B |
| Shares outstanding | 82.32M |
| Revenue | $434.25M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$606.64M |
| Revenue Q/Q | 23.27% |
| Revenue Y/Y | 19.52% |
| P/E ratio | -5.89 |
|---|---|
| EV/Sales | 7.83 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 8.22 |
| P/B ratio | 13.00 |
| Book/Share | 3.34 |
| Cash/Share | 2.59 |
| EPS | -$7.37 |
|---|---|
| ROA | -44.74% |
| ROE | -369.54% |
| Debt/Equity | 4.41 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.61 |
| Quick ratio | 2.49 |